首页 > 最新文献
paperpass

Oncoimmunology最新文献

英文 中文
STAT3 inhibition for the induction of immunogenic cell death in multiple myeloma. STAT3抑制诱导多发性骨髓瘤免疫原性细胞死亡。
IF 6.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-12-31 Epub Date: 2026-09-15 DOI: 10.1080/2162402X.2026.2732727
Oliver Kepp, Guido Kroemer

In a recent paper published in Blood Science, Sha et al. report that STAT3 inhibition eliminates multiple myeloma stem-like cells while eliciting hallmarks of immunogenic cell death. These highly intriguing findings connect stemness, integrated stress response, and antitumor immunity, yet in vivo validation remains necessary before this strategy can be considered immunogenic.

在最近发表在《血液科学》杂志上的一篇论文中,Sha等人报道了STAT3抑制可消除多发性骨髓瘤干细胞样细胞,同时引发免疫原性细胞死亡的标志。这些非常有趣的发现将干细胞、综合应激反应和抗肿瘤免疫联系起来,但在该策略被认为具有免疫原性之前,还需要进行体内验证。
{"title":"STAT3 inhibition for the induction of immunogenic cell death in multiple myeloma.","authors":"Oliver Kepp, Guido Kroemer","doi":"10.1080/2162402X.2026.2732727","DOIUrl":"10.1080/2162402X.2026.2732727","url":null,"abstract":"<p><p>In a recent paper published in <i>Blood Science</i>, Sha et al. report that STAT3 inhibition eliminates multiple myeloma stem-like cells while eliciting hallmarks of immunogenic cell death. These highly intriguing findings connect stemness, integrated stress response, and antitumor immunity, yet in vivo validation remains necessary before this strategy can be considered immunogenic.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2732727"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13580471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148971919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
X‑ray FLASH RT inhibits lung cancer bone metastasis via activating CD4⁺ T-cell‑mediated antitumor immunity with modulation of Th17 cell response. X射线FLASH RT通过激活CD4 + t细胞介导的抗肿瘤免疫和调节Th17细胞反应抑制肺癌骨转移。
IF 6.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-12-31 Epub Date: 2026-09-17 DOI: 10.1080/2162402X.2026.2706271
Yao Huang, Tao Wu, Wen Yang, Yuan-Yuan Liang, Yun-Fei Sun, Chao-Fan Ma, Ruo Tang, Rui-Ci Liang, Xue-Ting Zheng, Hui-Wen Luo, Cheng-He Ding, Xiao-An Li, Yan Zhou

Lung cancer is characterized by rapid progression and poor prognosis, with 50%-70% of patients presenting local or distant metastasis at diagnosis, among which bone metastasis is the most common type. Radiotherapy is the standard approach for managing cancerous bone metastasis pain. Here, we report the first application of X-ray FLASH radiotherapy (RT) in treating lung cancer bone metastasis in mice. Using an intratibial LLC-luc cell injection model, mice were treated with FLASH RT (94 Gy/s) or conventional RT (CONV RT, 0.1 Gy/s) via a petal accelerator developed by the Institute of Fluid Physics, China Academy of Engineering Physics. The results demonstrated that X-ray FLASH RT and CONV RT exhibited comparable efficacy in suppressing tumor growth, and both may alleviate osteolytic lesions in mice with lung cancer bone metastasis through CD4⁺ T cell-dependent antitumor responses. However, FLASH RT further attenuated bone destruction by inhibiting osteoclastogenesis, remodeling the bone-tumor microenvironment, and reducing tumor invasion, with lower systemic toxicity. Notably, unlike CONV RT, FLASH RT instigates a distinct DNA damage response that drives oxygen depletion, thereby attenuating ROS accumulation. This mechanistic cascade sequentially suppresses cGAS-STING-NF-κB axis activation and dampens the ensuing inflammatory response. In addition, we observed a reduction in Th17 cell differentiation following FLASH RT compared to CONV RT, which may contribute to the differential efficacy of these two radiation modalities in attenuating lung cancer bone metastasis. Collectively, X-ray FLASH RT provides a promising therapeutic strategy for patients with bone metastases.

肺癌的特点是进展快,预后差,50%-70%的患者在诊断时出现局部或远处转移,其中骨转移是最常见的类型。放射治疗是治疗癌性骨转移疼痛的标准方法。在这里,我们报道了x射线FLASH放疗(RT)在治疗小鼠肺癌骨转移中的首次应用。采用胫骨内lc -luc细胞注射模型,通过中国工程物理研究院流体物理研究所研制的叶片加速器,分别给予FLASH RT (94 Gy/s)或常规RT (CONV RT, 0.1 Gy/s)治疗。结果表明,x射线FLASH RT和CONV RT在抑制肿瘤生长方面具有相当的疗效,两者都可能通过CD4 + T细胞依赖的抗肿瘤反应减轻肺癌骨转移小鼠的溶骨性病变。然而,FLASH RT通过抑制破骨细胞生成,重塑骨肿瘤微环境,减少肿瘤侵袭,进一步减轻骨破坏,具有较低的全身毒性。值得注意的是,与CONV RT不同的是,FLASH RT会引发一种独特的DNA损伤反应,从而导致氧气消耗,从而减弱ROS积累。这一机制级联依次抑制cGAS-STING-NF-κB轴的激活并抑制随后的炎症反应。此外,我们观察到与CONV放疗相比,FLASH放疗后Th17细胞分化减少,这可能是这两种放疗方式在减轻肺癌骨转移方面疗效不同的原因。总的来说,x射线FLASH RT为骨转移患者提供了一种有希望的治疗策略。
{"title":"X‑ray FLASH RT inhibits lung cancer bone metastasis via activating CD4⁺ T-cell‑mediated antitumor immunity with modulation of Th17 cell response.","authors":"Yao Huang, Tao Wu, Wen Yang, Yuan-Yuan Liang, Yun-Fei Sun, Chao-Fan Ma, Ruo Tang, Rui-Ci Liang, Xue-Ting Zheng, Hui-Wen Luo, Cheng-He Ding, Xiao-An Li, Yan Zhou","doi":"10.1080/2162402X.2026.2706271","DOIUrl":"10.1080/2162402X.2026.2706271","url":null,"abstract":"<p><p>Lung cancer is characterized by rapid progression and poor prognosis, with 50%-70% of patients presenting local or distant metastasis at diagnosis, among which bone metastasis is the most common type. Radiotherapy is the standard approach for managing cancerous bone metastasis pain. Here, we report the first application of X-ray FLASH radiotherapy (RT) in treating lung cancer bone metastasis in mice. Using an intratibial LLC-luc cell injection model, mice were treated with FLASH RT (94 Gy/s) or conventional RT (CONV RT, 0.1 Gy/s) via a petal accelerator developed by the Institute of Fluid Physics, China Academy of Engineering Physics. The results demonstrated that X-ray FLASH RT and CONV RT exhibited comparable efficacy in suppressing tumor growth, and both may alleviate osteolytic lesions in mice with lung cancer bone metastasis through CD4⁺ T cell-dependent antitumor responses. However, FLASH RT further attenuated bone destruction by inhibiting osteoclastogenesis, remodeling the bone-tumor microenvironment, and reducing tumor invasion, with lower systemic toxicity. Notably, unlike CONV RT, FLASH RT instigates a distinct DNA damage response that drives oxygen depletion, thereby attenuating ROS accumulation. This mechanistic cascade sequentially suppresses cGAS-STING-NF-κB axis activation and dampens the ensuing inflammatory response. In addition, we observed a reduction in Th17 cell differentiation following FLASH RT compared to CONV RT, which may contribute to the differential efficacy of these two radiation modalities in attenuating lung cancer bone metastasis. Collectively, X-ray FLASH RT provides a promising therapeutic strategy for patients with bone metastases.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2706271"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13596902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148992133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NK cell-mediated tumor cell killing by bispecific innate cell engagers induces ADCC-mediated activation of primary human dendritic cells. NK细胞介导的双特异性先天细胞接合体杀伤肿瘤细胞诱导adc介导的原代人树突状细胞活化。
IF 6.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-12-31 Epub Date: 2026-01-18 DOI: 10.1080/2162402X.2026.2613561
Lukas Heger, Tomasz Kaszubowski, Lukas Amon, Christian H K Lehmann, Susanne Wingert, José Medina-Echeverz, Joachim Koch, Holger Hackstein, Ariawan Purbojo, Arndt Hartmann, Christoph Alexiou, Robert Cesnjevar, Jens Pahl, Diana Dudziak

Bispecific antibodies are used for the treatment of hematological malignancies as well as solid tumors. One of their main effector mechanisms is the recruitment of effector cells such as CD8+ T cells and CD16A+ NK cells to tumor cells. Bispecific innate cell engagers (ICE®) harnessing CD16A+ NK cells have been shown to induce significant tumor cell lysis in preclinical models, translating to promising signs of clinical activity together with a well-managed safety profile. However, how killing of tumor cells by NK cells influences other innate immune cells in the tumor microenvironment, such as dendritic cells (DCs), instrumental in bridging innate and adaptive tumor immunity, is largely unknown. Thus, we here analyzed whether antibody-dependent cell-mediated cytotoxicity by NK cells affected human DC subpopulations. We could show that killing of tumor cells leads to a strong activation of human conventional DCs type 1 (cDC1), DC2, and DC3 with enhanced expression of co-stimulatory molecules as well as the secretion of proinflammatory cytokines. Further, DC subpopulations as well as surviving tumor cells showed increased expression of the immunoregulatory molecule PD-L1 that is known to dampen T-cell immunity. Nevertheless, ADCC boosted the capacity of cDC1 and DC2 to prime naïve T cell responses but not of DC3. Thus, our data suggests that the therapy with bispecific antibodies targeting NK cells may have the potential to facilitate adaptive antitumor immune responses via activation of cDC1 and DC2.

双特异性抗体用于治疗恶性血液病和实体瘤。它们的主要效应机制之一是将CD8+ T细胞和CD16A+ NK细胞等效应细胞募集到肿瘤细胞。利用CD16A+ NK细胞的双特异性先天细胞接合器(ICE®)在临床前模型中已被证明可诱导显著的肿瘤细胞裂解,转化为有希望的临床活性迹象以及管理良好的安全性。然而,NK细胞杀死肿瘤细胞如何影响肿瘤微环境中的其他先天免疫细胞,如树突状细胞(dc),这在很大程度上是未知的,树突状细胞有助于桥接先天和适应性肿瘤免疫。因此,我们在这里分析了NK细胞的抗体依赖性细胞介导的细胞毒性是否影响人类DC亚群。我们可以证明,杀死肿瘤细胞会导致人类常规dc 1型(cDC1)、DC2和DC3的强烈激活,并增强共刺激分子的表达以及促炎细胞因子的分泌。此外,DC亚群以及存活的肿瘤细胞显示免疫调节分子PD-L1的表达增加,这是已知的抑制t细胞免疫的分子。然而,ADCC提高了cDC1和DC2的能力,以启动naïve T细胞反应,而不是DC3。因此,我们的数据表明,针对NK细胞的双特异性抗体治疗可能通过激活cDC1和DC2来促进适应性抗肿瘤免疫反应。
{"title":"NK cell-mediated tumor cell killing by bispecific innate cell engagers induces ADCC-mediated activation of primary human dendritic cells.","authors":"Lukas Heger, Tomasz Kaszubowski, Lukas Amon, Christian H K Lehmann, Susanne Wingert, José Medina-Echeverz, Joachim Koch, Holger Hackstein, Ariawan Purbojo, Arndt Hartmann, Christoph Alexiou, Robert Cesnjevar, Jens Pahl, Diana Dudziak","doi":"10.1080/2162402X.2026.2613561","DOIUrl":"10.1080/2162402X.2026.2613561","url":null,"abstract":"<p><p>Bispecific antibodies are used for the treatment of hematological malignancies as well as solid tumors. One of their main effector mechanisms is the recruitment of effector cells such as CD8<sup>+</sup> T cells and CD16A<sup>+</sup> NK cells to tumor cells. Bispecific innate cell engagers (ICE®) harnessing CD16A<sup>+</sup> NK cells have been shown to induce significant tumor cell lysis in preclinical models, translating to promising signs of clinical activity together with a well-managed safety profile. However, how killing of tumor cells by NK cells influences other innate immune cells in the tumor microenvironment, such as dendritic cells (DCs), instrumental in bridging innate and adaptive tumor immunity, is largely unknown. Thus, we here analyzed whether antibody-dependent cell-mediated cytotoxicity by NK cells affected human DC subpopulations. We could show that killing of tumor cells leads to a strong activation of human conventional DCs type 1 (cDC1), DC2, and DC3 with enhanced expression of co-stimulatory molecules as well as the secretion of proinflammatory cytokines. Further, DC subpopulations as well as surviving tumor cells showed increased expression of the immunoregulatory molecule PD-L1 that is known to dampen T-cell immunity. Nevertheless, ADCC boosted the capacity of cDC1 and DC2 to prime naïve T cell responses but not of DC3. Thus, our data suggests that the therapy with bispecific antibodies targeting NK cells may have the potential to facilitate adaptive antitumor immune responses via activation of cDC1 and DC2.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2613561"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12818816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145999482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies. meitreme和METIMMOX治疗转移性微卫星稳定型结直肠癌的一线化学免疫治疗临床试验的汇总分析
IF 6.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-12-31 Epub Date: 2026-06-20 DOI: 10.1080/2162402X.2026.2671491
Caroline Truntzer, Marion Thibaudin, Paula Anna Bousquet, Morgane Peroz, Valentin Derangère, Alis Ilie, David Rageot, Kjersti Flatmark, Anne Hansen Ree, Sebastian Meltzer, François Ghiringhelli

Background: Colorectal cancer with microsatellite stable (MSS) status is intrinsically resistant to immune checkpoint inhibitor monotherapy targeting PD-1 or PD-L1. However, emerging evidence suggests that chemotherapies may overcome this resistance when combined with immunotherapy.

Methods: We conducted a pooled analysis of individual patient data from two phase II trials evaluating oxaliplatin-based chemotherapy combined with checkpoint inhibitors as first-line treatment for MSS metastatic colorectal cancer. The MEDITREME trial is a single-arm study assessing durvalumab and tremelimumab with oxaliplatin-based chemotherapy, while the METIMMOX trial is a randomized study comparing standard oxaliplatin-based chemotherapy with an alternating regimen of oxaliplatin-based chemotherapy and nivolumab. We compared overall survival (OS), progression-free survival (PFS), and response rates between patients treated with chemotherapy alone versus chemoimmunotherapy, and evaluated the association between these outcomes and transcriptomic and immunoscore data.

Results: A total of 130 patients were included: 38 who received chemotherapy alone and 92 chemoimmunotherapy. The median OS was significantly improved in the chemoimmunotherapy group compared with chemotherapy alone (not reached vs. 15.3 months; HR = 0.58; 95% CI, 0.36-0.96; p = 0.03). The complete response rates were higher with chemoimmunotherapy (14% vs. 5%). No significant differences were observed in PFS. High baseline CD8+ T-cell infiltration was associated with improved outcomes in patients receiving chemoimmunotherapy but not in those treated with chemotherapy alone.

Conclusions: This pooled analysis provides compelling evidence supporting the clinical benefit of first-line chemoimmunotherapy in a subset of patients with MSS mCRC. Baseline CD8+ T-cell infiltration may serve as a predictive biomarker for identifying patients most likely to benefit from this treatment approach.

背景:微卫星稳定(MSS)状态的结直肠癌本质上对靶向PD-1或PD-L1的免疫检查点抑制剂单药治疗具有耐药性。然而,新出现的证据表明,当化疗与免疫治疗联合使用时,可能会克服这种耐药性。方法:我们对来自两项II期试验的个体患者数据进行了汇总分析,评估基于奥沙利铂的化疗联合检查点抑制剂作为MSS转移性结直肠癌的一线治疗。MEDITREME试验是一项评估durvalumab和tremelimumab与奥沙利铂为基础的化疗的单臂研究,而METIMMOX试验是一项比较标准奥沙利铂为基础的化疗与奥沙利铂为基础的化疗和纳武单抗交替方案的随机研究。我们比较了单独化疗与化疗免疫治疗患者的总生存期(OS)、无进展生存期(PFS)和缓解率,并评估了这些结果与转录组学和免疫评分数据之间的关系。结果:共纳入130例患者,其中单独化疗38例,化疗免疫治疗92例。与单独化疗相比,化疗免疫治疗组的中位OS显著改善(未达到vs. 15.3个月;HR = 0.58; 95% CI, 0.36-0.96; p = 0.03)。化疗免疫治疗的完全缓解率更高(14% vs. 5%)。PFS无明显差异。在接受化疗免疫治疗的患者中,高基线CD8+ t细胞浸润与改善预后相关,而在单独化疗的患者中则没有。结论:这项汇总分析提供了令人信服的证据,支持一线化疗免疫治疗对一部分MSS mCRC患者的临床益处。基线CD8+ t细胞浸润可以作为一种预测性生物标志物,用于识别最有可能从这种治疗方法中受益的患者。
{"title":"Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.","authors":"Caroline Truntzer, Marion Thibaudin, Paula Anna Bousquet, Morgane Peroz, Valentin Derangère, Alis Ilie, David Rageot, Kjersti Flatmark, Anne Hansen Ree, Sebastian Meltzer, François Ghiringhelli","doi":"10.1080/2162402X.2026.2671491","DOIUrl":"10.1080/2162402X.2026.2671491","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer with microsatellite stable (MSS) status is intrinsically resistant to immune checkpoint inhibitor monotherapy targeting PD-1 or PD-L1. However, emerging evidence suggests that chemotherapies may overcome this resistance when combined with immunotherapy.</p><p><strong>Methods: </strong>We conducted a pooled analysis of individual patient data from two phase II trials evaluating oxaliplatin-based chemotherapy combined with checkpoint inhibitors as first-line treatment for MSS metastatic colorectal cancer. The MEDITREME trial is a single-arm study assessing durvalumab and tremelimumab with oxaliplatin-based chemotherapy, while the METIMMOX trial is a randomized study comparing standard oxaliplatin-based chemotherapy with an alternating regimen of oxaliplatin-based chemotherapy and nivolumab. We compared overall survival (OS), progression-free survival (PFS), and response rates between patients treated with chemotherapy alone <i>versus</i> chemoimmunotherapy, and evaluated the association between these outcomes and transcriptomic and immunoscore data.</p><p><strong>Results: </strong>A total of 130 patients were included: 38 who received chemotherapy alone and 92 chemoimmunotherapy. The median OS was significantly improved in the chemoimmunotherapy group compared with chemotherapy alone (not reached <i>vs</i>. 15.3 months; HR = 0.58; 95% CI, 0.36-0.96; <i>p</i> = 0.03). The complete response rates were higher with chemoimmunotherapy (14% <i>vs</i>. 5%). No significant differences were observed in PFS. High baseline CD8<sup>+</sup> T-cell infiltration was associated with improved outcomes in patients receiving chemoimmunotherapy but not in those treated with chemotherapy alone.</p><p><strong>Conclusions: </strong>This pooled analysis provides compelling evidence supporting the clinical benefit of first-line chemoimmunotherapy in a subset of patients with MSS mCRC. Baseline CD8<sup>+</sup> T-cell infiltration may serve as a predictive biomarker for identifying patients most likely to benefit from this treatment approach.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2671491"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13285599/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148297094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estradiol-associated extracellular signaling in the human breast in vivo identifies mast cells as tumor-supportive stromal mediators. 人乳腺中雌二醇相关的细胞外信号在体内识别肥大细胞作为肿瘤支持基质介质。
IF 6.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-12-31 Epub Date: 2026-10-13 DOI: 10.1080/2162402X.2026.2746847
Annelie Abrahamsson, Xingyue Wang, Wen Zhong, Charlotta Dabrosin

Sex steroid exposure is a major risk factor for breast cancer initiation and progression through incompletely understood mechanisms. Novel therapeutics for prevention and treatment of estrogen-dependent breast cancer are needed. Cell-cell interactions within the microenvironment contribute to breast cancer progression through extracellular signaling. Here, extracellular proteins were sampled directly from live normal human breast tissue and breast cancers using microdialysis, and 1,101 proteins were quantified. Mechanistic studies were performed in cultured intact normal human breast tissue and mast cells. Findings were validated in vivo using ER+ breast cancer models in immunocompetent and immunocompromised mice and in a zebrafish xenograft model. We identified a breast tissue-specific extracellular protein signature comprising 150 proteins associated with local estradiol (E2) levels, of which several were linked to mast cell biology, including stem cell factor (SCF). Human ER+ breast tumors exhibited increased extracellular SCF levels and higher mast cell density, which was associated with poorer overall survival. In normal human breast tissue, E2 increased mast cell abundance and activity. In vitro, E2 rapidly activated mast cells, an effect blocked by desloratadine. In mouse breast cancer models, E2 increased and fulvestrant reduced mast cell density. In the zebrafish, mast cells promoted ER+ breast cancer growth, which was further enhanced by E2 and abrogated by desloratadine. Overall, our findings identify mast cells as estrogen-responsive stromal mediators and support targeting mast cell-dependent pathways as a potential strategy for the prevention and treatment of estrogen-dependent breast cancer.

{"title":"Estradiol-associated extracellular signaling in the human breast <i>in vivo</i> identifies mast cells as tumor-supportive stromal mediators.","authors":"Annelie Abrahamsson, Xingyue Wang, Wen Zhong, Charlotta Dabrosin","doi":"10.1080/2162402X.2026.2746847","DOIUrl":"10.1080/2162402X.2026.2746847","url":null,"abstract":"<p><p>Sex steroid exposure is a major risk factor for breast cancer initiation and progression through incompletely understood mechanisms. Novel therapeutics for prevention and treatment of estrogen-dependent breast cancer are needed. Cell-cell interactions within the microenvironment contribute to breast cancer progression through extracellular signaling. Here, extracellular proteins were sampled directly from live normal human breast tissue and breast cancers using microdialysis, and 1,101 proteins were quantified. Mechanistic studies were performed in cultured intact normal human breast tissue and mast cells. Findings were validated <i>in vivo</i> using ER<sup>+</sup> breast cancer models in immunocompetent and immunocompromised mice and in a zebrafish xenograft model. We identified a breast tissue-specific extracellular protein signature comprising 150 proteins associated with local estradiol (E2) levels, of which several were linked to mast cell biology, including stem cell factor (SCF). Human ER<sup>+</sup> breast tumors exhibited increased extracellular SCF levels and higher mast cell density, which was associated with poorer overall survival. In normal human breast tissue, E2 increased mast cell abundance and activity. <i>In vitro</i>, E2 rapidly activated mast cells, an effect blocked by desloratadine. In mouse breast cancer models, E2 increased and fulvestrant reduced mast cell density. In the zebrafish, mast cells promoted ER<sup>+</sup> breast cancer growth, which was further enhanced by E2 and abrogated by desloratadine. Overall, our findings identify mast cells as estrogen-responsive stromal mediators and support targeting mast cell-dependent pathways as a potential strategy for the prevention and treatment of estrogen-dependent breast cancer.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2746847"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13671425/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149185336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biomarkers of subclinical cholestasis predict cancer immunotherapy outcomes. 亚临床胆汁淤积的生物标志物预测癌症免疫治疗结果。
IF 6.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-12-31 Epub Date: 2026-10-15 DOI: 10.1080/2162402X.2026.2748140
Anne-Laure Mallard de La Varende, Marine Fidelle, Guido Kroemer, Laurence Zitvogel

In a recent paper published in Cancer Cell, we identified subclinical cholestasis as an accessible imprint of gut dysbiosis predicting resistance to immune checkpoint blockade. Our work connects γ-glutamyl transferase, bile-acid remodeling, and MAdCAM-1 loss to compromised antitumor immunity, opening avenues for novel biomarker-guided microbiota interventions.

{"title":"Biomarkers of subclinical cholestasis predict cancer immunotherapy outcomes.","authors":"Anne-Laure Mallard de La Varende, Marine Fidelle, Guido Kroemer, Laurence Zitvogel","doi":"10.1080/2162402X.2026.2748140","DOIUrl":"10.1080/2162402X.2026.2748140","url":null,"abstract":"<p><p>In a recent paper published in Cancer Cell, we identified subclinical cholestasis as an accessible imprint of gut dysbiosis predicting resistance to immune checkpoint blockade. Our work connects <i>γ</i>-glutamyl transferase, bile-acid remodeling, and MAdCAM-1 loss to compromised antitumor immunity, opening avenues for novel biomarker-guided microbiota interventions.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2748140"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13679315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149197394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glioblastoma immune landscape remodeling following treatment with CD70-targeted CAR-T cells. cd70靶向CAR-T细胞治疗后胶质母细胞瘤免疫景观重塑。
IF 6.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-12-31 Epub Date: 2026-10-18 DOI: 10.1080/2162402X.2026.2745295
Alexandros Kourtesakis, Dennis Alexander Agardy, Clara Tejido Dierssen, Ling Hai, Dirk Carsten Frieder Hoffmann, Normann Mussnig, Ralph Sinn, Manuel Fischer, Andy Schacht, Michael Breckwoldt, Lukas Bunse, Tim Sauer, Michael Platten, Wolfgang Wick, Tobias Kessler

Chimeric antigen receptor (CAR)-T cell therapy has shown limited efficacy in glioblastoma (GB), largely because of the immunosuppressive tumor microenvironment (TME). We have previously demonstrated that the ligand-based mCD70-directed construct mCAR27 specifically eliminates CD70⁺ GB cells in vitro, and induces durable tumor remission with prolonged survival in a syngeneic model of orthotopic GB. Despite the therapeutic promise of CD70 as a GB CAR-T cell target, the impact of CD70-directed CAR-T cells on the brain tumor immune landscape after target interception remains unexplored. Here, we independently confirmed a tumorigenic role for CD70 in murine GB by performing bulk RNA sequencing and in vivo experiments. Next, we applied single-cell RNA sequencing (scRNAseq) to decipher the transcriptome of GB-infiltrating immune cells in immunocompetent mice bearing CD70+ GB after intratumoral mCAR27 therapy. CAR-T cell treatment expanded adoptively transferred cells and was associated with increased endogenous Cd8⁺ T-cell infiltration, alongside a reduction in immunosuppressive populations, including Tregs and anti-inflammatory M2-like macrophages, but also subsets of dendritic and natural-killer cells. CD70 expression was detected on multiple GB-infiltrating immune subsets, notably Tregs and M2-like macrophages. Transcriptionally, mCAR27-mediated GB remission led to a coordinated downregulation of type-I interferon-stimulated genes and immunosuppressive mediators such as Arg1, Tgfbi, Cd274, Pdcd1lg2 and Lag3, coupled with upregulation of genes involved in inflammatory resolution, findings consistent with attenuation of GB-derived inflammatory stress and immunosuppression. Collectively, we showcase that CD70-directed CAR-T cell therapy remodels the post-treatment immune landscape towards resolution of inflammation and reduced immunosuppression, supporting sustained immune surveillance.

嵌合抗原受体(CAR)-T细胞治疗在胶质母细胞瘤(GB)中显示出有限的疗效,主要是因为免疫抑制肿瘤微环境(TME)。我们之前已经证明了基于mcd70的配体定向构建体mCAR27在体外特异性地消除CD70 + GB细胞,并在原位GB的同基因模型中诱导持久的肿瘤缓解和延长的生存期。尽管CD70作为GB CAR-T细胞靶标具有治疗前景,但靶向CD70的CAR-T细胞在靶标拦截后对脑肿瘤免疫景观的影响仍未被探索。在这里,我们独立地通过大量RNA测序和体内实验证实了CD70在小鼠GB中的致瘤作用。接下来,我们应用单细胞RNA测序(scRNAseq)技术,对转染CD70+ GB的免疫功能小鼠瘤内mCAR27治疗后的GB浸润免疫细胞转录组进行了解码。CAR-T细胞治疗扩大过继转移细胞,并与内源性Cd8 + t细胞浸润增加相关,同时免疫抑制群体减少,包括Tregs和抗炎m2样巨噬细胞,以及树突状细胞和自然杀伤细胞亚群。CD70在多个gb浸润免疫亚群中表达,特别是treg和m2样巨噬细胞。在转录方面,mcar27介导的GB缓解导致i型干扰素刺激基因和免疫抑制介质(如Arg1、Tgfbi、Cd274、Pdcd1lg2和Lag3)的协同下调,以及参与炎症消退的基因的上调,研究结果与GB源性炎症应激和免疫抑制的衰减一致。总之,我们展示了cd70导向的CAR-T细胞疗法重塑了治疗后的免疫景观,以解决炎症和减少免疫抑制,支持持续的免疫监视。
{"title":"Glioblastoma immune landscape remodeling following treatment with CD70-targeted CAR-T cells.","authors":"Alexandros Kourtesakis, Dennis Alexander Agardy, Clara Tejido Dierssen, Ling Hai, Dirk Carsten Frieder Hoffmann, Normann Mussnig, Ralph Sinn, Manuel Fischer, Andy Schacht, Michael Breckwoldt, Lukas Bunse, Tim Sauer, Michael Platten, Wolfgang Wick, Tobias Kessler","doi":"10.1080/2162402X.2026.2745295","DOIUrl":"10.1080/2162402X.2026.2745295","url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR)-T cell therapy has shown limited efficacy in glioblastoma (GB), largely because of the immunosuppressive tumor microenvironment (TME). We have previously demonstrated that the ligand-based mCD70-directed construct mCAR27 specifically eliminates CD70⁺ GB cells <i>in vitro</i>, and induces durable tumor remission with prolonged survival in a syngeneic model of orthotopic GB. Despite the therapeutic promise of CD70 as a GB CAR-T cell target, the impact of CD70-directed CAR-T cells on the brain tumor immune landscape after target interception remains unexplored. Here, we independently confirmed a tumorigenic role for CD70 in murine GB by performing bulk RNA sequencing and <i>in vivo</i> experiments. Next, we applied single-cell RNA sequencing (scRNAseq) to decipher the transcriptome of GB-infiltrating immune cells in immunocompetent mice bearing CD70<sup>+</sup> GB after intratumoral mCAR27 therapy. CAR-T cell treatment expanded adoptively transferred cells and was associated with increased endogenous Cd8⁺ T-cell infiltration, alongside a reduction in immunosuppressive populations, including T<sub>regs</sub> and anti-inflammatory M2-like macrophages, but also subsets of dendritic and natural-killer cells. CD70 expression was detected on multiple GB-infiltrating immune subsets, notably T<sub>regs</sub> and M2-like macrophages. Transcriptionally, mCAR27-mediated GB remission led to a coordinated downregulation of type-I interferon-stimulated genes and immunosuppressive mediators such as <i>Arg1</i>, <i>Tgfbi</i>, <i>Cd274</i>, <i>Pdcd1lg2</i> and <i>Lag3</i>, coupled with upregulation of genes involved in inflammatory resolution, findings consistent with attenuation of GB-derived inflammatory stress and immunosuppression. Collectively, we showcase that CD70-directed CAR-T cell therapy remodels the post-treatment immune landscape towards resolution of inflammation and reduced immunosuppression, supporting sustained immune surveillance.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2745295"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13682394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alistipes and Eggerthella shape the response to oncolytic adenovirus therapy in mice and humans through short-chain fatty acid metabolism. Alistipes和Eggerthella通过短链脂肪酸代谢在小鼠和人类中形成对溶瘤腺病毒治疗的反应。
IF 6.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-12-31 Epub Date: 2026-04-09 DOI: 10.1080/2162402X.2026.2656514
Mirte van der Heijden, James Hugo Armstrong Clubb, Pande Putu Erawijantari, Aki Ronkainen, Victor Arias, Elise Jirovec, Tatiana Kudling, Santeri Artturi Pakola, Nea Ojala, Lyna Haybout, Saru Basnet, Susanna Grönberg-Vähä-Koskela, Sini Karoliina Raatikainen, Otto Hemminki, Anna Kanerva, Dafne Carolina Alves Quixabeira, Victor Cervera-Carrascon, João Manuel Dos Santos, Leo Lahti, Akseli Hemminki

Accumulating evidence implicates the microbiome as an important determinant of clinical outcomes in cancer therapies; however, the role of the microbiome in oncolytic virus therapy remains largely unexplored. We investigated the gut microbiome of cancer patients following treatment with the oncolytic adenovirus igrelimogene litadenorepvec (Ad5/3-E2F-d24-hTNF-IRES-hIL2; TILT-123). Baseline fecal samples from phase I clinical trials (NCT04695327 and NCT05271318) were analyzed using shotgun metagenomic sequencing and compared to treatment outcomes. A higher relative abundance of Alistipes was observed in patients with treatment benefit, while elevated Eggerthella was observed with reduced benefit. These associations were validated in a preclinical mouse model where administration of Alistipes shahii improved the efficacy of adenovirus therapy. In addition, enrichment analysis in patient samples showed a positive correlation between higher relative abundance of Alistipes and elevated short-chain fatty acids in both feces and serum, which in turn revealed higher circulating neutrophil counts. Finally, in a case study, we observed that adenovirus treatment resulted in increased Alistipes relative abundance and reduced Eggerthella relative abundance, indicating that adenovirus therapy may beneficially modulate the microbiome. Overall, our findings reveal a novel association between Alistipes, Eggerthella, and the therapeutic response to oncolytic adenovirus therapy, highlighting their potential as biomarkers or targets for microbiome-based interventions such as pre-, pro-, or postbiotics.

越来越多的证据表明,微生物组是癌症治疗临床结果的重要决定因素;然而,微生物组在溶瘤病毒治疗中的作用在很大程度上仍未被探索。我们研究了溶瘤腺病毒igrelimogene litadenorepvec治疗后癌症患者的肠道微生物组(Ad5/3-E2F-d24-hTNF-IRES-hIL2; TILT-123)。I期临床试验(NCT04695327和NCT05271318)的基线粪便样本使用霰弹枪宏基因组测序进行分析,并与治疗结果进行比较。在治疗获益的患者中观察到Alistipes的相对丰度较高,而Eggerthella的升高则观察到获益降低。这些关联在临床前小鼠模型中得到验证,其中给予Alistipes shahii可提高腺病毒治疗的疗效。此外,患者样本的富集分析显示,粪便和血清中Alistipes相对丰度较高与短链脂肪酸升高呈正相关,这反过来又表明循环中性粒细胞计数较高。最后,在一个案例研究中,我们观察到腺病毒治疗导致Alistipes相对丰度增加,而Eggerthella相对丰度降低,这表明腺病毒治疗可能有益地调节微生物组。总的来说,我们的研究结果揭示了Alistipes、Eggerthella和溶瘤腺病毒治疗反应之间的新关联,突出了它们作为生物标志物或基于微生物组的干预靶点的潜力,如前、前或后生化。
{"title":"<i>Alistipes</i> and <i>Eggerthella</i> shape the response to oncolytic adenovirus therapy in mice and humans through short-chain fatty acid metabolism.","authors":"Mirte van der Heijden, James Hugo Armstrong Clubb, Pande Putu Erawijantari, Aki Ronkainen, Victor Arias, Elise Jirovec, Tatiana Kudling, Santeri Artturi Pakola, Nea Ojala, Lyna Haybout, Saru Basnet, Susanna Grönberg-Vähä-Koskela, Sini Karoliina Raatikainen, Otto Hemminki, Anna Kanerva, Dafne Carolina Alves Quixabeira, Victor Cervera-Carrascon, João Manuel Dos Santos, Leo Lahti, Akseli Hemminki","doi":"10.1080/2162402X.2026.2656514","DOIUrl":"10.1080/2162402X.2026.2656514","url":null,"abstract":"<p><p>Accumulating evidence implicates the microbiome as an important determinant of clinical outcomes in cancer therapies; however, the role of the microbiome in oncolytic virus therapy remains largely unexplored. We investigated the gut microbiome of cancer patients following treatment with the oncolytic adenovirus igrelimogene litadenorepvec (Ad5/3-E2F-d24-hTNF-IRES-hIL2; TILT-123). Baseline fecal samples from phase I clinical trials (NCT04695327 and NCT05271318) were analyzed using shotgun metagenomic sequencing and compared to treatment outcomes. A higher relative abundance of <i>Alistipes</i> was observed in patients with treatment benefit, while elevated <i>Eggerthella</i> was observed with reduced benefit. These associations were validated in a preclinical mouse model where administration of <i>Alistipes shahii</i> improved the efficacy of adenovirus therapy. In addition, enrichment analysis in patient samples showed a positive correlation between higher relative abundance of <i>Alistipes</i> and elevated short-chain fatty acids in both feces and serum, which in turn revealed higher circulating neutrophil counts. Finally, in a case study, we observed that adenovirus treatment resulted in increased <i>Alistipes</i> relative abundance and reduced <i>Eggerthella</i> relative abundance, indicating that adenovirus therapy may beneficially modulate the microbiome. Overall, our findings reveal a novel association between <i>Alistipes</i>, <i>Eggerthella</i>, and the therapeutic response to oncolytic adenovirus therapy, highlighting their potential as biomarkers or targets for microbiome-based interventions such as pre-, pro-, or postbiotics.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2656514"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13374768/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147647081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex-based considerations in the choice for a TLR9 or TLR7/8 agonist to arm the sentinel lymph node in early-stage melanoma. 选择TLR9或TLR7/8激动剂武装早期黑色素瘤前哨淋巴结的性别考虑
IF 6.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-12-31 Epub Date: 2026-05-07 DOI: 10.1080/2162402X.2026.2662708
Jessica C L Notohardjo, Elisa C Toffoli, Tara Muijlwijk, Mari F C M van den Hout, Vinitha Kandiah, Mariette Labots, Rieneke van de Ven, Alfons J M van den Eertwegh, Tanja D de Gruijl

Intradermal delivery of the Toll-like receptor (TLR)-9 agonist agatolimod/CPG7909, prior to sentinel lymph node (SLN) biopsy was previously shown to induce locoregional and systemic immunity, reduce tumor-involved SLN rates, and improve recurrence-free survival in patients with early-stage melanoma. Remarkably, men exhibited superior dendritic cell (DC) maturation. Here, we report on further sex-based differences in the immune response after intradermal administration of CPG7909, which included higher CD80/CD83 expression levels in conventional (c) DC subsets in men's as compared to women's SLN, as well as higher ex-vivo release levels of IL-1β, TNF, and IL-6 (all contributors to cDC activation) and Th1/Th2 cytokines. In an effort to identify a more effective DC-activating therapy for women, we compared the in-vitro effects of CPG7909 with those of the TLR7/8 agonist resiquimod/R848 on SLN single cells from female patients. R848 induced superior cDC subset activation and TNF, IL-6, IL-10, IL-12, IFNγ, and CXCL10 release. Correlation analyses suggested that IFNα, TNF, and IL-6 were key for CPG7909-induced LNR-cDC activation, whereas R848's effect appeared more cytokine-independent. We conclude that combining locally delivered CPG7909 and R848 in early-stage melanoma will ensure full-range DC subset activation and robust pro-inflammatory T-cell responses in melanoma SLN, independent of sex.

在前哨淋巴结(SLN)活检前皮内给药toll样受体(TLR)-9激动剂agatolimod/CPG7909曾被证明可诱导局部和全身免疫,降低肿瘤累及的SLN率,并提高早期黑色素瘤患者的无复发生存率。值得注意的是,男性树突状细胞(DC)成熟程度更高。在这里,我们报告了皮内给药CPG7909后免疫反应的进一步基于性别的差异,包括与女性SLN相比,男性常规DC亚群中CD80/CD83表达水平更高,IL-1β、TNF和IL-6(所有cDC激活的贡献者)和Th1/Th2细胞因子的体外释放水平更高。为了寻找一种更有效的女性dc激活疗法,我们比较了CPG7909和TLR7/8激动剂雷昔莫特/R848对女性患者SLN单细胞的体外作用。R848诱导了优异的cDC亚群激活和TNF、IL-6、IL-10、IL-12、IFNγ和CXCL10的释放。相关分析表明,IFNα、TNF和IL-6是cpg7909诱导的LNR-cDC激活的关键,而R848的作用似乎更不依赖于细胞因子。我们得出结论,在早期黑色素瘤中联合局部递送的CPG7909和R848将确保黑色素瘤SLN中全范围的DC亚群激活和强大的促炎t细胞反应,与性别无关。
{"title":"Sex-based considerations in the choice for a TLR9 or TLR7/8 agonist to arm the sentinel lymph node in early-stage melanoma.","authors":"Jessica C L Notohardjo, Elisa C Toffoli, Tara Muijlwijk, Mari F C M van den Hout, Vinitha Kandiah, Mariette Labots, Rieneke van de Ven, Alfons J M van den Eertwegh, Tanja D de Gruijl","doi":"10.1080/2162402X.2026.2662708","DOIUrl":"10.1080/2162402X.2026.2662708","url":null,"abstract":"<p><p>Intradermal delivery of the Toll-like receptor (TLR)-9 agonist agatolimod/CPG7909, prior to sentinel lymph node (SLN) biopsy was previously shown to induce locoregional and systemic immunity, reduce tumor-involved SLN rates, and improve recurrence-free survival in patients with early-stage melanoma. Remarkably, men exhibited superior dendritic cell (DC) maturation. Here, we report on further sex-based differences in the immune response after intradermal administration of CPG7909, which included higher CD80/CD83 expression levels in conventional (c) DC subsets in men's as compared to women's SLN, as well as higher <i>ex-vivo</i> release levels of IL-1β, TNF, and IL-6 (all contributors to cDC activation) and Th1/Th2 cytokines. In an effort to identify a more effective DC-activating therapy for women, we compared the in-vitro effects of CPG7909 with those of the TLR7/8 agonist resiquimod/R848 on SLN single cells from female patients. R848 induced superior cDC subset activation and TNF, IL-6, IL-10, IL-12, IFNγ, and CXCL10 release. Correlation analyses suggested that IFNα, TNF, and IL-6 were key for CPG7909-induced LNR-cDC activation, whereas R848's effect appeared more cytokine-independent. We conclude that combining locally delivered CPG7909 and R848 in early-stage melanoma will ensure full-range DC subset activation and robust pro-inflammatory T-cell responses in melanoma SLN, independent of sex.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2662708"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13166185/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147844759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Local delivery of SBRT and IL-12 to murine PDAC tumors modulates hematopoiesis. 小鼠PDAC肿瘤局部递送SBRT和IL-12可调节造血功能。
IF 6.2 2区 医学 Q1 IMMUNOLOGY Pub Date : 2026-12-31 Epub Date: 2026-06-05 DOI: 10.1080/2162402X.2026.2682058
Tara G Vrooman, Emily R Quarato, Gary Hannon, Noah A Salama, Maggie L Lesch, Angela L Hughson, Vedika S Chandak, Nataliia Vdovichenko, Zhiming Jin, Ronald Lakony, Jian Ye, Sarah L Eckl, Sidney Lesser, Edith M Lord, David C Linehan, Haoming Qiu, Nadia Luheshi, Jim Eyles, Laura M Calvi, Scott A Gerber

Standard of care radiotherapy and chemotherapy have shown limited efficacy in pancreatic ductal adenocarcinoma (PDAC). Immunotherapy has emerged as a promising treatment but has been hindered by systemic toxicities. A shift from systemic to localized delivery has reduced adverse effects and improved response rates in various cancers. However, the impact of tumor-targeted therapies on distant tissues, such as the bone marrow, remains underexplored. In a murine model of PDAC, we treated tumors with targeted stereotactic body radiation therapy (SBRT) and intratumoral interleukin-12 mRNA (IL-12). We evaluated tumor, blood, and bone marrow cells for therapy-induced changes over a period of 13 d to 13 months. Our results showed that while SBRT/IL-12 locally eradicated primary tumors, it also induced significant effects in the bone marrow. Early effects included acute lymphopenia in the blood and an immunostimulatory response in the bone marrow, leading to increased hematopoiesis. Long-term effects involved a reduction in hematopoietic stem cells (HSCs) and a shift towards a myeloid lineage, suggesting potential premature aging of the HSC population. These findings highlight the profound impact of localized SBRT/IL-12 therapy on distal bone marrow, emphasizing the need for further investigation into the long-term immunological consequences of localized cancer treatments.

标准护理放疗和化疗对胰腺导管腺癌(PDAC)的疗效有限。免疫疗法已成为一种很有前途的治疗方法,但一直受到全身毒性的阻碍。从全身给药到局部给药的转变减少了各种癌症的不良反应,提高了反应率。然而,肿瘤靶向治疗对远端组织(如骨髓)的影响仍未得到充分探索。在小鼠PDAC模型中,我们使用靶向立体定向体放射治疗(SBRT)和瘤内白细胞介素-12 mRNA (IL-12)治疗肿瘤。我们在13天至13个月的时间内评估肿瘤、血液和骨髓细胞治疗引起的变化。我们的研究结果表明,SBRT/IL-12在局部根除原发肿瘤的同时,也在骨髓中诱导了显著的作用。早期的影响包括血液中的急性淋巴细胞减少和骨髓中的免疫刺激反应,导致造血增加。长期影响包括造血干细胞(HSC)的减少和向髓系的转变,表明HSC群体可能过早衰老。这些发现强调了局部SBRT/IL-12治疗对远端骨髓的深远影响,强调需要进一步研究局部癌症治疗的长期免疫后果。
{"title":"Local delivery of SBRT and IL-12 to murine PDAC tumors modulates hematopoiesis.","authors":"Tara G Vrooman, Emily R Quarato, Gary Hannon, Noah A Salama, Maggie L Lesch, Angela L Hughson, Vedika S Chandak, Nataliia Vdovichenko, Zhiming Jin, Ronald Lakony, Jian Ye, Sarah L Eckl, Sidney Lesser, Edith M Lord, David C Linehan, Haoming Qiu, Nadia Luheshi, Jim Eyles, Laura M Calvi, Scott A Gerber","doi":"10.1080/2162402X.2026.2682058","DOIUrl":"10.1080/2162402X.2026.2682058","url":null,"abstract":"<p><p>Standard of care radiotherapy and chemotherapy have shown limited efficacy in pancreatic ductal adenocarcinoma (PDAC). Immunotherapy has emerged as a promising treatment but has been hindered by systemic toxicities. A shift from systemic to localized delivery has reduced adverse effects and improved response rates in various cancers. However, the impact of tumor-targeted therapies on distant tissues, such as the bone marrow, remains underexplored. In a murine model of PDAC, we treated tumors with targeted stereotactic body radiation therapy (SBRT) and intratumoral interleukin-12 mRNA (IL-12). We evaluated tumor, blood, and bone marrow cells for therapy-induced changes over a period of 13 d to 13 months. Our results showed that while SBRT/IL-12 locally eradicated primary tumors, it also induced significant effects in the bone marrow. Early effects included acute lymphopenia in the blood and an immunostimulatory response in the bone marrow, leading to increased hematopoiesis. Long-term effects involved a reduction in hematopoietic stem cells (HSCs) and a shift towards a myeloid lineage, suggesting potential premature aging of the HSC population. These findings highlight the profound impact of localized SBRT/IL-12 therapy on distal bone marrow, emphasizing the need for further investigation into the long-term immunological consequences of localized cancer treatments.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2682058"},"PeriodicalIF":6.2,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13245092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148164827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Oncoimmunology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
mjeditor
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1